CTLA4 and neoplasm: Inhibiting immune checkpoints by impeding the CTLA-4 or PD-1/PD-L1 axis could therefore reduce the immune escaping of tumor cells and represent a potential immunotherapeutic approach (Fig. 5) [159, 160].